California-based biotech Iovance Biotherapeutics announced today that its autologous tumor-infiltrating lymphocyte therapy lifileucel (Amtagvi) led to objective responses in 18 of the 41 patients (44% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results